Markets

AveXis prices upsized IPO at $20 midpoint

AveXis, an early-stage biotech developing a gene therapy for spinal muscular atrophy, raised $95 million in an upsized IPO by offering 4.75 million shares at $20, the midpoint of the range of $19 to $21. The company originally planned to offer 4.25 million shares. Existing investors had indicated an interest in buying $30 million on the IPO, which would represent 32% of the deal. AveXis plans to list on the Nasdaq under the symbol AVXS. Goldman Sachs and Jefferies acted as lead managers on the deal.

The article AveXis prices upsized IPO at $20 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs